Articles tagged with Glioblastomas
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A retrospective study found that patients who underwent regular surveillance imaging after surgery had similar median survival rates to those who only returned when they felt symptoms of recurrence. The results suggest less frequent imaging could improve patient convenience and reduce costs.
New research from Penn Medicine suggests blocking the Wnt pathway can make chemotherapy more effective against glioblastoma. The study found that targeting stromal cells, which act like stem cells and promote tumor growth, may be an effective way to overcome treatment resistance.
A retrospective study by researchers at UC San Francisco found that removing the non-contrast-enhancing tumor increases survival for adults with glioblastoma. Patients with IDH-mutant tumors who underwent resections of both contrast-enhancing and non-contrast-enhancing tumor had a significantly longer average survival time, around 37.3...
The Akay Lab has developed a new microfluidic brain cancer chip that can simultaneously administer multiple drugs and assess their response to glioblastoma cells. The device enables fast drug combination testing in as little as two weeks, potentially improving patient survival rates.
UC San Diego researchers identified αvβ5 integrin as the key contributor to Zika virus' ability to infect brain cells. Blocking this integrin with antibodies or small molecule inhibitors effectively prevents Zika virus from infecting both normal brain stem cells and cancer stem cells.
A new study found that reinforcing the meningeal lymphatic network increases tumor antigen traffic from the meninges to lymph nodes, triggering activation of immune cells against the tumor. This approach combines with existing immunotherapy for effective glioblastoma eradication.
Scientists have found a novel method to combat glioblastoma, a deadly brain tumor, by introducing VEGF-C into the cerebrospinal fluid of mice. This approach significantly extended survival rates when combined with immune system checkpoint inhibitors, offering new hope for treatment options.
Researchers at Mount Sinai are exploring new treatments for brain tumors, including magnetic hyperthermia therapy and studies on glioma dormancy and tumor microenvironment. The grant funding will support five-year projects focused on improving patient outcomes through innovative therapies.
Researchers have developed glioblastoma organoids from patient tissue, allowing them to rapidly test personalized treatment strategies. The models retain features from the primary tumor and can be used to explore ways to attack it.
Researchers at Massachusetts General Hospital and the University of Florida have identified a promising strategy to make glioblastoma susceptible to immune checkpoint inhibitors. The approach targets chemokine receptors that allow myeloid-derived suppressor cells to infiltrate tumors, leading to immunosuppression and treatment resistance.
A study by researchers at the University of Texas M.D. Anderson Cancer Center identified a subset of immune macrophages that resist treatment with anti-PD-1 checkpoint blockade in glioblastoma patients. The team found that these CD73-expressing macrophages were associated with decreased survival, and that targeting them with combinatio...
A study found that glioblastoma patients with a history of Human cytomegalovirus (HCMV) infection had a significantly shorter survival rate, highlighting the potential use of HCMV testing to predict treatment outcomes. The presence of HCMV antibodies was linked to a four-month reduction in life expectancy.
Researchers found that MALT1 levels correlate with patient survival in brain cancer, and blocking the gene with MALT1 inhibitors causes glioblastoma stem cells to undergo cellular suicide. This discovery points to the potential of further exploring MALT1 inhibitors as a treatment for glioblastoma.
The Ivy Brain Tumor Center is collaborating with SonALAsense to develop and test sonodynamic therapy, a promising new treatment for recurrent glioblastoma. The Phase 0/2 clinical trial will assess the safety and efficacy of this non-invasive therapy in patients with glioblastoma.
Researchers discovered that SNAP, a nitric oxide donor, overcomes TMZ resistance in glioblastoma multiforme (GBM) cells by reducing MGMT protein stability. This finding offers a potential strategy to improve treatment outcomes for patients with GBM.
Researchers at Karolinska Institutet have identified 10 novel glioblastoma-specific endothelial cell transcripts that could represent potential tumour-targets for therapy. The study uses a new method to process human brain tissue data and identifies disease-related changes in cells lining tumour blood vessels.
Researchers developed a blood test that measures cell-free DNA (cfDNA) to predict prognosis in glioblastoma patients. The test correlates with progression-free survival and detects genetic mutations not found in solid tissue biopsies, offering a complementary view of the tumor's molecular profile.
A compound has been identified as effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs), a major challenge in treating this devastating cancer. The research also showed that the compound is non-toxic to normal cells, raising hopes for developing drugs with low toxicity.
University of Minnesota Medical School researchers have made a breakthrough in combating glioblastoma, the most common form of adult brain cancer. By combining ultrasound with engineered glass particles, they were able to create a 'Goldilocks' balance that awakens the body's immune response and boosts the effectiveness of immunotherapy.
Researchers at the Spanish National Research Council (CSIC) have found that glioblastoma hijacks pericytes to promote tumor progression and evade the immune system. By targeting chaperone-mediated autophagy, they may develop a new therapeutic approach to treat this aggressive brain cancer.
Researchers at the University of Georgia have discovered a new use for an existing insulin compound to treat glioblastoma, a fast-growing and often fatal form of brain cancer. The study found that surfen-treated cells were blocked from tumor growth and the spread of tumor cells in the brain.
Scientists at USC and UC San Diego have discovered a potential novel target for treating glioblastoma, the deadliest form of brain cancer. They found that targeting the circadian clock in tumor stem cells can disrupt the growth and development of the tumor, leading to its death.
Researchers at Cleveland Clinic have identified FGF2 as a novel druggable target for glioblastoma, the most common primary malignant brain tumor. The study reveals that FGF2 is an intermediary in a multi-step pro-cancer signaling loop, suggesting that targeting it may halt the growth and spread of glioblastoma.
Researchers at Texas A&M University have found that the AH receptor can actually block invasion of glioblastoma cells, rather than promoting it. Adding certain ligands to the receptor has been shown to inhibit cell invasion and provide additional protection to the brain.
A study published in Acta Neuropathologica Communications found that interregional differences in the somatic genetic landscape of glioblastoma affect prognosis. The research analyzed Japanese patients with IDH-wildtype GBM and discovered a biomarker, triple CNA, associated with survival duration.
Researchers at the University of Sussex have identified novel biomarkers in bodily fluids that could signal the presence of glioblastoma. These biomarkers are associated with extracellular vesicles and may enable a simpler way to test for the tumor, rather than a biopsy.
A clinical trial found that an oral activator, veledimex, controlled the transcription of human interleukin-12, reducing toxicity while preserving anti-tumor effects. Patients with recurrent glioblastoma had improved overall survival rates, with some experiencing up to 17.8 months of survival.
A two-step gene therapy treatment has shown promise in treating recurrent glioblastoma by boosting IL-12 production and enhancing antitumor immune cell infiltration. The treatment has also been found to be safe, with serious side effects easily reversible after discontinuing treatment.
Researchers found that adding MS drug teriflunomide to targeted cancer therapy significantly shrinks glioblastoma tumors and improves mouse survival. The treatment targets cancer stem cells, which are responsible for tumor recurrence.
A Phase 0 clinical trial shows ribociclib effectively targets glioblastoma cells and breaks the blood-brain barrier, offering a new treatment hope. The study identifies a potential mechanism of drug resistance, paving the way for a combined-drug regimen to overcome resistance.
A study identified Glycerol-3-phosphate dehydrogenase 1 (GPD1) as a molecular marker specific to dormant glioma stem cells. GPD1-producing cells are resistant to chemotherapy and radiation, and their activation leads to tumor relapse.
Researchers found that inhibiting ID1 slows tumour progression in glioblastoma, breast and melanoma. Targeting the protein with medication may present a promising strategy for patients.
A recent study found that only 5.5% of glioblastoma patients survive five years after diagnosis, highlighting the need for more aggressive treatments to improve long-term survival. The research analyzed 48,652 cases and identified factors associated with five-year survival, including age, race, gender, and treatment with radiotherapy.
Research at MD Anderson Cancer Center discovers a symbiotic circuit between PTEN-deficient glioblastoma cells and macrophages, which creates a mutually supportive relationship. Inhibiting LOX, a novel attractor of macrophages, shrinks tumors and blocks macrophage infiltration.
Researchers paired a calorie-restricted ketogenic diet with a tumor-inhibiting antibiotic to destroy cancer stem cells and mesenchymal cells in glioblastoma, a fast-moving brain cancer. The combination killed tumor cells while reversing disease symptoms and improving mouse survival.
Researchers at IRB Barcelona discovered that the antibody mAb806 can be used to treat many types of tumors with EGFR mutations, not just a specific one. The study also found that even non-mutated EGFR can be treated to make it susceptible to mAb806 therapy.
Researchers from FEFU and international partners discover potential targets for glioblastoma multiforme treatment by studying proteins in the WNT signaling pathway. The findings could lead to improved antitumor therapy outcome through suppression of cancer stem cells, accelerating tumor growth rate.
Researchers discovered multiple potential targets for glioblastoma by systematically profiling patient-derived brain tumour cells. They found that adult glioblastoma cells rely on genes important for brain development in infancy, highlighting the need for new research to understand the developing human brain.
Scientists identified a molecular driver of glioblastoma, a highly aggressive and treatment-resistant brain cancer, by analyzing cell-by-cell genetic data. Researchers found that reprogramming primitive oligodendrocyte progenitors into stem-like cells plays a key role in glioma initiation and progression.
A new experimental glioblastoma vaccine developed by Jefferson and Imvax has shown promising results in a phase Ib clinical trial. The treatment was found to slow tumor recurrence and prolong patient survival in patients with newly diagnosed glioblastoma multiforme.
Researchers identified three key genetic drivers of glioblastoma development, including the activation of telomerase. Early tumors exhibit concurrent genetic alterations, but recurrent tumors display distinct mutation patterns. This study highlights the need for new treatments to effectively target resistant subclones.
A team of researchers discovered a way to make glioblastoma brain tumors more sensitive to radiation by blocking the activity of a specific protein, PTEN. This breakthrough could lead to improved treatment prospects for patients with this aggressive form of brain cancer.
Researchers at the University of Bonn have reported significant progress in treating aggressive brain tumors like glioblastoma. Combination chemotherapy with CCNU and temozolomide significantly prolongs patients' survival time, with a notable benefit for those with methylated MGMT promoter.
Research reveals that patients with specific MAPK mutations are more likely to respond to immunotherapy drugs in glioblastoma. The study also found that tumors with PTEN mutations were less responsive to treatment, suggesting new targets for treatment development.
A multidisciplinary team of researchers has developed a human induced pluripotent stem cell (IPSC) derived 3D organoid model for drug testing. The system demonstrated anti-tumor efficacy with doxorubicin and predicted clinical response to temozolomide, offering a more personalized approach to treating glioblastoma.
A study by MGH researchers reveals that brain tumors use existing blood vessels to resist anti-angiogenic drugs, leading to compression and stimulation of angiogenesis. The study suggests targeting vessel co-option before using anti-angiogenic drugs could be an effective strategy for glioblastoma treatment.
Researchers at MD Anderson Cancer Center have discovered a link between FGL2 protein and glioblastoma progression. FGL2, known for suppressing the immune system, is highly expressed in GBM and can be eliminated by knocking it out, eliminating tumor progression in mice with intact immune systems.
A new method of using multiple microRNAs to weaken cancer cells has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The treatment strategy weakens tumor cells but does not directly kill them, making it an advantage for further treatment.
A recent study has found that standard treatment for glioblastoma is more effective in women than men, with tumor growth velocity showing a steady decline after treatment. The researchers identified distinct molecular signatures of the disease in men and women, which could lead to sex-specific treatment strategies.
Researchers at McGill University Health Centre found a gene called EGFRvIII that changes the content of messages exchanged between cells, leading to aggressive brain cancer glioblastoma. This discovery holds promise for developing tests and tailored treatments for patients with glioblastoma.
A team of University of Arizona researchers discovered a protein called WIF-1 that might increase survival in glioblastoma patients. Long-term survivors rely on genes that suppress the Wnt signaling pathway, which fuels tumor growth. The study aims to create a drug targeting this pathway for more precise treatment.
Researchers at Virginia Tech have discovered a drug that can block the spread of glioblastoma, the deadliest form of brain cancer, by halting the rapid movement of fluid within the body. The breakthrough finding could lead to improved treatment options for patients with glioblastoma.
Researchers have developed a new tool to study genetic switches in glioblastoma tumors, which drive cancer growth and survival. The new technique uses ChRO-seq data to classify tumors into subtypes based on active switches, with potential applications in predicting patient outcomes and developing new therapies.
A nationwide Finnish study found that brain cancer survival has improved overall, with younger patients experiencing significant gains in median survival time. However, elderly patients saw minimal improvement, highlighting the need for more effective treatment strategies for this growing patient population.
Researchers at Barrow Neurological Institute have developed a new clinical trial regimen for treating glioblastoma, a complex brain tumor. The study demonstrates the ability of the drug AZD1775 to penetrate brain tissue and provide clinically-relevant activity against human glioblastoma.
Researchers have successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells in mice, offering a potential new treatment option. The vaccine demonstrated effectiveness in delaying tumor development and prolonging survival time in mouse models.
Researchers at UTMB successfully adapted a Zika virus vaccine to target and kill glioblastoma, the deadliest form of brain tumor. The altered vaccine effectively destroyed cancerous brain cells in mice without harming healthy ones.
Scientists at Virginia Tech Carilion Research Institute have identified a potential strategy in fighting brain cancer by targeting a gene associated with circadian rhythms. Inhibiting this gene may inhibit cancer stem cells from renewing themselves and differentiating into glioblastoma cells.
The Ben and Catherine Ivy Foundation has partnered with Barrow Neurological Institute to fund a $50 million effort to accelerate drug discovery and clinical testing for glioblastoma. The new Ivy Brain Tumor Center aims to provide individualized experimental therapies to malignant brain tumor patients worldwide.
Researchers identified epigenetic changes that accompany glioblastoma progression and predict patient survival. DNA methylation sequencing can be used to predict clinically relevant tumor properties.